This year’s report reveals a significant shift in the industry, with M&A investment projected to total $130 billion in 2024 — a 41% decrease from $222 billion in 2023. Despite this decline in value, deal volume remains stable, with biopharma deals increasing by 17% compared to last year. Companies are now focusing on earlier-stage opportunities that offer lower price tags.

Join us as we explore:

• The critical role of dealmaking in driving growth within life sciences.
• Key therapeutic areas that are shaping the future of M&A.
• Emerging growth opportunities in AI startups and China biotech.
• Strategies for effective deal execution to achieve strong ROI.

Register